Journal of the Korean Applied Science and Technology (한국응용과학기술학회지)

The Korean Society of Applied Science and Technology (한국응용과학기술학회)
권호 표지
DOI QR코드

DOI QR Code

Synthesis and Melanoma Inhibitory Activity of New Aminoisoquinolinylamide Derivatives

새로운 Aminoisoquinolinylamide 유도체의 합성 및 흑색종 저해 효능

  • Yoo, Kyung-Ho (Biomaterials Research Center, Korea Institute of Science and Technology) ;
  • Cho, Hye-Jung (Biomaterials Research Center, Korea Institute of Science and Technology)
  • 유경호 (한국과학기술연구원 바이오소재연구센터) ;
  • 조혜정 (한국과학기술연구원 바이오소재연구센터)
  • Published : 2009.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

In this work, a novel series of aminoisoquinolinylamide derivatives 1a-c and 2a-f were synthesized via several reaction steps, starting from 2-methyl-4-nitrobenzonitrile (3) and 1-chloro-5-nitroquinoline (8). And their antiproliferative activities were screened against A375 human melanoma cell line compared to Sorafenib as a reference compound. Among them, compound 1b and 1c exhibited meaningful inhibitory activities. These results demonstrated that aminoisoquinolinylamide scaffold possesses the possibility as the treatment for melanoma.

Keywords

References

  1. B. J. Druker and N. B. Lydon, Lessons Learned from the Development of an Abl Tyrosine Kinase Inhibitor for Chronic Myelogenous Leukemia, J. Clin. Invest., 105, 3 (2000) https://doi.org/10.1172/JCI9083
  2. D. Raben, B. A. Helfrich, D. Chan, G. Johnson, and P. A. Bunn, Jr., ZD1839, A Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Alone and in Combination with Radiation and Chemotherapy as a New Therapeutic Strategy in Non-small Cell Lung Cancer, Semin. Oneol., 29 (Supplement 4), 37 (2002)
  3. R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. M. Clark, P. Santabarbara, and P. Bonomi, Determinants of Tumor Response and Survival with Erlotinib in Patients with Non - Small-Cell Lung Cancer, J. Clin. Oneol., 22, 3238 (2004) https://doi.org/10.1200/JCO.2004.11.057
  4. F. R. Gruijl, UV Carcinogenesis and Melanocytes, Pigment Cell Res., 16, 591 (2003)
  5. C. Garbe, A. Hauschild, M. V olkenandt, D. Schadendorf, W. Stolz, u. Reinhold, R. D. Kortmann, C. Kettelhack, B. Frerich, U. Keilholz, R. Dummer, G. Sebastian, W. Tilgen, G. Schuler, A. Mackensen, and R. Kaufmann, Evidence and Interdisciplinary Consense-based German Guidelines: Diagnosis and Surveillance of Melanoma, Melanoma Res., 17, 393 (2007) https://doi.org/10.1097/CMR.0b013e3282f05039
  6. J. A. Carlson, J. S. Ross, A. Slominski, G. Linette, J. Mysliborski, J. Hill, and M. Mihm, Jr., Molecular Diagnostics in Melanoma, J. Am Acad. Dermntol., 52, 743 (2005) https://doi.org/10.1016/j.jaad.2004.08.034
  7. A. C. Buzaid and C. M. Anderson, The Changing Prognosis of Melanoma, Curro Oneol. Rep., 2, 322 (2000) https://doi.org/10.1007/s11912-000-0025-9
  8. M. R. Middleton, J. J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates, B. Dreno, M. Henz, D. Schadendorf, A. Kapp, J. Weiss, U. Fraass, P. Statkevich, M. Muller, and N. Thatcher, Randomized Phase III Study of Temozolomide versus Dacarbazine in the Treatment of Patients with Advanced Metastatic Malignant Melanoma, J. Clin. Oneal., 18, 158 (2008)
  9. A. Y. Bedikian, M. Mill ward, H. Pehamberger, R. Conry, M. Gore, U. Trefzer, A. C. Pavlick, R. DeConti, E. M. Hersh, P. Hersey, J. M. Kirkwood, and F. G. Haluska, Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group, J. Clin. Oneol., 24, 4738 (2006) https://doi.org/10.1200/JCO.2006.06.0483
  10. D. H. Lawson, Choices in Adkuvant Trerapy of Melanoma, Cancer Control, 12, 236 (2005) https://doi.org/10.1177/107327480501200405
  11. S. A. Rosenburg, M. T. Lotze, J. C. Yang, P. M. Aebersold, W. M. Linehan, C. A. Seipp, and D. E. White, Experience with the Use of High Dose Interleukin-2 in the Treatment of 652 Cancer Patients, Ann. Surg., 210, 474 (1989) https://doi.org/10.1097/00000658-198910000-00008
  12. M. B. Atkins, M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, and S. A. Rosenberg, High-dose Recombinant Interleukin 2 Therapy for Patients with Metastatic Melanoma: Analysis of 270 Patients Treated between 1985 and 1993, J. Clin. Oneol., 17, 2105 (1999) https://doi.org/10.1200/JCO.1999.17.7.2105
  13. C. M. Anderson, A. C. Buzaid, and S. S. Legha, Systemic Treatments for Advanced Cutaneous Melanoma, Oncology, 9, 1149 (1995)
  14. L. Serrone, M. Zeuli, F. M. Sega, and F. Cognetti, therapy Dacarbazine-based Chemofor Metastatic Melanoma: Thirty-year Experience Overview, J. Exp. Clin. Cancer Res., 19, 21 (2000)
  15. W. S. Fletcher, D. S. Daniels, V. K. Sondak, B. Dana, R. Townsend, H. E. Hynes, L. F. Hutchins, and J. R. Pancoast. Evaluation of Cisplatin and DTIC in Inoperable Stage III and IV Melanoma, Am J. Clin. Oneol., 16, 359 (1993) https://doi.org/10.1097/00000421-199308000-00018
  16. X. Zhang, A. Nirschl, Y. Zou, and E. S. Priestley, Phenylglycinarnide and Pyridylglycinamide Derivatives Useful as Anticoagulants, WO 07/002313
  17. L. V. Dubey, and I. V. Dubey, Side Reactions of Onium Coupling Reagents BOP and HBTV in the Synthesis of Silica Polymer Supports, Ukr. Bioorg. Acta, 1, 13 (2005)
  18. S. A. Gamage, J. A. Spicer, G. W. Rewcastle, J. Milton, S. Sohal, W. Dangerfield, P. Mistry, N. Vicker, P. A. Charlton, and W. A. Denny, Structure-activity Relationships for Pyrido-, Imidazo-, Pyrazolo-, Pyrazino-, and Pyrrolophenazinecarboxamides as Topoisomerase-targeted Anticancer Agents, J. Med. Chern., 45, 740 (2002) https://doi.org/10.1021/jm010330+
  19. S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch, Preclinical Overview of Sorafenib, a Multikinase Inhibitor that Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling, Mol. Cancer Ther., 7, 3129 (2008) https://doi.org/10.1158/1535-7163.MCT-08-0013